Staphylococcal lipoteichoic acid inhibits delayed-type hypersensitivity reactions via the platelet-activating factor receptor

Journal of Clinical Investigation

Volumn 115, Issue 10, 2005, Pages 2855-2861

  Zhang, Qiwei ^a   Mousdicas, Nico ^a   Yi, Qiaofang ^a   Al Hassani, Mohammed ^a   Billings, Steven D ^a   Perkins, Susan M ^a   Howard, Katherine M ^b   Ishii, Satoshi ^c   Shimizu, Takao ^c   Travers, Jeffrey B ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 HEXADECYL 2 N METHYLCARBAMOYLGLYCEROPHOSPHOCHOLINE; INTERLEUKIN 10; LIPOTEICHOIC ACID; NEUTRALIZING ANTIBODY; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ATOPIC DERMATITIS; BACTERIAL CELL WALL; BACTERIAL INFECTION; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; DELAYED HYPERSENSITIVITY; GRAM POSITIVE BACTERIUM; HUMAN; HUMAN CELL; HYPERSENSITIVITY REACTION; IMMUNE RESPONSE; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; RAT; SKIN DISEASE; SKIN INFLAMMATION; STAPHYLOCOCCUS AUREUS; WILD TYPE;

ANIMALS; CALCIUM; CELL LINE; DERMATITIS, ATOPIC; DINITROFLUOROBENZENE; DRUG HYPERSENSITIVITY; DRUG SYNERGISM; HUMANS; HYPERSENSITIVITY, DELAYED; INFLAMMATION; INTERLEUKIN-10; LIPOPOLYSACCHARIDES; MICE; MICE, KNOCKOUT; PLATELET ACTIVATING FACTOR; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTORS, G-PROTEIN-COUPLED; SKIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TEICHOIC ACIDS; TH1 CELLS; TH2 CELLS;

EID: 26444530080     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI25429     Document Type: Article

References (38)

1. Leung, D.Y. 2003. Infection in atopic dermatitis. Curr. Opin. Pediatr. 15:399-404.
2. Spergel, J.M., and Paller, A.S. 2003. Atopic dermatitis and the atopic march. J. Allergy Clin. Immunol. 112:S128-S139.
3. Ong, P.Y., et al. 2002. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. 347:1151-1160.
4. McCormick, J.K., Yarwood, J.M., and Schlievett, P.M. 2001. Toxic shock syndrome and bacterial superantigens: an update [review]. Annu. Rev. Microbiol. 55:77-104.
5. Travers, J.B., Notris, D.A., and Leung, D.Y. 2001. The keratinocyte as a target for staphylococcal bacterial toxins. J. Investig. Dermatol. Symp. Proc. 6:225-230.
6. Ezepchuk, Y.V., et al. 1996. Staphylococcal toxins and protein A differentially induce cytotoxicity and release of tumor necrosis factor-alpha from human keratinocytes. J. Invest. Dermatol. 107:603-609.
7. Walev, I., et al. 1993. Staphylococcal alpha-toxin kills human keratinocytes by permeabilizing the plasma membrane for monovalent ions. Infect. Immun. 61:4972-4979.
8. Schwandner, R., Dziarski, R., Wesche, H., Rothe, M., and Kirschning, C.J. 1999. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J. Biol. Chem. 274:17406-17409.
9. Michelsen, K.S., et al. 2001. The role of toll-like receptors (TLRs) in bacteria-induced maturation of murine dendritic cells (DCS). Peptidoglycan and lipoteichoic acid are inducers of DC maturation and require TLR2. J. Biol. Chem. 276:25680-25686.
10. Lemjabbar, H., and Basbaum, C. 2002. Platelet-activating factor receptor and ADAM10 mediate responses to Staphylococcus aureus in epithelial cells. Nat. Med. 8:41-46.
11. Cundell, D.R., Gerard, N.P., Gerard, C., Idanpaan-Heikkila, I., and Tuomanen, E.I. 1995. Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Nature. 377:435-438.
12. Garcia Rodriguez, C., et al. 1995. The role of N-glycosylation for functional expression of the human platelet-activating factor receptor. Glycosylation is required for efficient membrane trafficking. J. Biol. Chem. 270:25178-25184.
13. Prescott, S.M., Zimmerman, G.A., Stafforini, D.A., and McIntyre, T.M. 2000. Platelet-activating factor and related lipid mediators. Annu. Rev. Biochem. 69:419-445.
14. Michel, L., et al. 1990. Production of paf-acether by human epidermal cells. J. Invest. Dermatol. 95:576-581.
15. Travers, J.B., et al. 1996. Platelet-activating factor biosynthesis induced by various stimuli in human HaCaT keratinocytes. J. Invest. Dermatol. 107:88-94.
16. Travers, J.B. 1999. Oxidative stress can activate the epidermal platelet-activating factor receptor. J. Invest. Dermatol. 112:279-283.
17. Alappatt, C., Johnson, C.A., Clay, K.L., and Travers, J.B. 2000. Acute keratinocyte damage stimulates platelet-activating factor production. Arch. Dermatol. Res. 292:256-259.
18. Pei, Y., et al. 1998. Activation of the epidermal platelet-activating factor receptor results in cytokine and cyclooxygenase-2 biosynthesis. J. Immunol. 161:1954-1961.
19. Dy, L.C., Pei, Y., and Travers, J.B. 1999. Augmentation of ultraviolet B radiation-induced tumor necrosis factor production by the epidermal platelet-activating factor receptor. J. Biol. Chem. 274:26917-26921.
20. Southall, M.D., et al. 2001. The epidermal platelet-activating factor receptor protects epidermal cells from TNF- and TRAIL-induced apoptosis through a nuclear factor kappa B-dependent process. J. Biol. Chem. 276:45548-45554.
21. Walterscheid, J.P., Ullrich, S.E., and Nghiem, D.X. 2002. Platelet-activating factor, a molecular sensor for cellular damage, activates systemic immune suppression. J. Exp. Med. 195:171-179.
22. Travers, J.B., et al. 1995. Identification of functional platelet-activating factor receptors on human keratinocytes. J. Invest. Dermatol. 105:816-823.
23. Re, F., and Strominger, J.L. 2001. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J. Biol. Chem. 276:37692-37699.
24. Ishii, S., et al. 1998 Impaired anaphylactic responses with intact sensitivity to endotoxin in mice lacking a platelet-activating factor receptor. J. Exp. Med. 187:1779-1788.
25. Travers, J.B., Pei, Y., Morin, S.M., and Hood, A.F. 1998. Antiinflammatory effects of the platelet-activating factor receptor antagonist A85783. Arch. Dermatol. Res. 290:569-573.
26. Shreedhar, V., Giese, T., Sung, V.W., and Ullrich, S.E. 1998. A cytokine cascade including prostaglandin E2, IL-4, and IL-10 is responsible for UV-induced systemic immune suppression. J. Immunol. 160:3783-3789.
27. Nghiem, D.X., et al. 2002. Mechanisms underlying the suppression of established immune responses by ultraviolet radiation. J. Invest. Dermatol. 119:600-608.
28. Williamson, P., and Kligman, A.M. 1965. A new method for the quantitative investigation of cutaneous bacteria. J. Invest. Dermatol. 45:498-503.
29. Grandel, K.E., Fart, R.S., Wanderer, A.A., Eisenstadt, T.C., and Wasserman, S.I. 1985. Association of platelet-activating factor with primary acquired cold urticaria. N. Engl. J. Med. 313:405-409.
30. Okubo, K., Karashima, T., Hachisuk, H., and Sasai, T. 1989. The existence of a PAF-like substance in blister fluid, derived from patients with bullous pemphigoid as demonstrated by human platelet aggregation. Kurume Med. J. 36:173-177.
31. Travers, J.B., et al. 1998. Identification and pharmacological characterization of platelet-activating factor and related 1-palmitoyl species in human inflammatory blistering diseases. Prostaglandins Other Lipid Mediat. 56:305-324.
32. Jenks, P.J., Kavanagh, G.M., Btooks, J., Btadfield, J.W., and Archer, C.B. 1999. Comparison of weal and flare responses to platelet activating factor (PAF) and histamine, and the ultrastructural effects of PAF in the skin of atopic and normal subjects. Clin. Exp. Dermatol. 24:112-117.
33. Stafforini, D.M., et al. 1999. Deficiency of platelet-activating fartor acetylhydrolase is a severity factor for asthma. J. Clin. Invest. 103:989-997.
34. Yang, X., Gartner, J., Zhu, L., Wang, S., and Brunham, R.C. 1999. IL-10 gene knockout mice show enhanced Th1-like protective immunity and absent granuloma formation following chlamydia trachomatis lung infection. J. Immunol. 162:1010-1017.
35. Travers, J.B., et al. 2003. Augmentation of staphylococcal alpha-toxin signaling by the epidermal platelet-activating factor receptor. J. Invest. Dermatol. 120:789-794.
36. Guadano, E.M., et al. 2004. Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study. Allergy. 59:766-771.
37. Petersen, J.E., et al. 2002. Enhanced cutaneous inflammatory reactions to aspergillus fumigatus in a murine model of chronic granulomatous disease J. Invest. Dermatol. 118:424-429.
38. Hanifin, J.M., and Rajka, G. 1980. Diagnostic features of atopic dermatitis. Acta Derm. Venereol. (Stockh.). 92:44-47.